These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7043439)

  • 21. Evaluation of sixteen anti-motion sickness drugs under controlled laboratory conditions.
    Wood CD; Graybiel A
    Aerosp Med; 1968 Dec; 39(12):1341-4. PubMed ID: 4881887
    [No Abstract]   [Full Text] [Related]  

  • 22. Scopolamine patch to prevent seasickness: clinical response vs. plasma concentration in sailors.
    Gil A; Nachum Z; Dachir S; Chapman S; Levy A; Shupak A; Adir Y; Tal D
    Aviat Space Environ Med; 2005 Aug; 76(8):766-70. PubMed ID: 16110693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transdermal scopolamine in the prevention of motion sickness at sea.
    Price NM; Schmitt LG; McGuire J; Shaw JE; Trobough G
    Clin Pharmacol Ther; 1981 Mar; 29(3):414-9. PubMed ID: 7009021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect on motion sickness and oculomotor function of GR 38032F, a 5-HT3-receptor antagonist with anti-emetic properties.
    Stott JR; Barnes GR; Wright RJ; Ruddock CJ
    Br J Clin Pharmacol; 1989 Feb; 27(2):147-57. PubMed ID: 2523720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transdermal scopolamine for motion sickness.
    Med Lett Drugs Ther; 1981 Oct; 23(21):89-90. PubMed ID: 7027000
    [No Abstract]   [Full Text] [Related]  

  • 26. Scopoderm: transdermal hyoscine for motion sickness.
    Drug Ther Bull; 1989 Nov; 27(23):91-2. PubMed ID: 2519317
    [No Abstract]   [Full Text] [Related]  

  • 27. The efficacy of hyoscine hydrobromide in reducing side-effects induced during immersion in virtual reality.
    Regan EC; Ramsey AD
    Aviat Space Environ Med; 1996 Mar; 67(3):222-6. PubMed ID: 8775399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Flunarizine in the therapy of chronic cerebrovascular insufficiency. Multicentric controlled study].
    Arrigo A; Lottici P; Alfonsi E; Terraneo GB
    Clin Ter; 1984 Sep; 110(6):541-8. PubMed ID: 6238768
    [No Abstract]   [Full Text] [Related]  

  • 29. Experimental assessment of selected antimotion drugs.
    Matsnev EI; Bodo D
    Aviat Space Environ Med; 1984 Apr; 55(4):281-6. PubMed ID: 6732678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain hypoxia in migraine: pathophysiologic and therapeutic implications.
    Amery WK
    J Cereb Blood Flow Metab; 1982; 2 Suppl 1():S62-5. PubMed ID: 7045147
    [No Abstract]   [Full Text] [Related]  

  • 31. Seasickness tables.
    COLES RR; HEAD PW
    J R Nav Med Serv; 1958; 44(3):205-13. PubMed ID: 13588669
    [No Abstract]   [Full Text] [Related]  

  • 32. Management of Sea Sickness in Susceptible Flight Crews.
    Powell-Dunford N; Bushby A
    Mil Med; 2017 Nov; 182(11):e1846-e1850. PubMed ID: 29087851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New treatment of confirmed seasickness; therapeutic results].
    MONNIER AJ
    Presse Med (1893); 1955 Feb; 63(13):240-1. PubMed ID: 14371477
    [No Abstract]   [Full Text] [Related]  

  • 34. Intermittent claudication: a controlled study in parallel time of the short-term and long-term effects of cinnarizine.
    Barber JH; Reuter CA; Jageneau AH; Loots W
    Pharmatherapeutica; 1980; 2(6):401-7. PubMed ID: 7433479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Image and quantity analysis of prostaglandin in rats' blood plasma and Na(+)-K(+)-ATPase in their cerebellum during the prevention of motion sickness by cinnarizine].
    Dong W; Tian D; Zhang M
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 1998 Jun; 15(2):151-4. PubMed ID: 12548903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Further experiments on the prevention of motion sickness.
    GLASER EM; HERVEY GR
    Lancet; 1952 Mar; 1(6706):490-2. PubMed ID: 14898786
    [No Abstract]   [Full Text] [Related]  

  • 37. Central effects of cinnarizine: restricted use in aircrew.
    Nicholson AN; Stone BM; Turner C; Mills SL
    Aviat Space Environ Med; 2002 Jun; 73(6):570-4. PubMed ID: 12056673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral vascular disease: cinnarizine et al.
    Drug Ther Bull; 1981 Mar; 19(7):27-8. PubMed ID: 7227205
    [No Abstract]   [Full Text] [Related]  

  • 39. The Vestibular Time Constant and Clinical Response to Antimotion Sickness Medication.
    Lagami D; Shupak A; Jamison A; Tal D
    Ear Hear; 2023 Nov-Dec 01; 44(6):1404-1409. PubMed ID: 37221635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of chronic urticaria with an inhibitor of complement activation (cinnarizine).
    Kalimo K; Jansen CT
    Ann Allergy; 1980 Jan; 44(1):34-7. PubMed ID: 7352689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.